In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

Replication research can take the temperature on how accurate science in a given field is, but research replication is easier ...

Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant Interim ...

Antibiotic resistance is one of the world's leading causes of death, claiming the lives of more people than HIV / AIDS or ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

Quest Diagnostics yesterday announced the launch of a new diagnostic test for Oropouche virus, a disease primarily spread by ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Nicotine vaping continues to outperform FDA-approved smoking cessation therapies in well-designed studies, including a new clinical trial conducted in Australia. This growing body of evidence badly ...